{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T23:58:30Z","timestamp":1794614310639,"version":"4.9.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01994-2","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T13:58:19Z","timestamp":1638280699000},"page":"148-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape"],"prefix":"10.1007","volume":"39","author":[{"given":"Christian W.","family":"Mende","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"issue":"3","key":"1994_CR1","first-page":"1","volume":"2013","author":"Kidney Disease: Improving Global Outcomes Work Group. KDIGO","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes Work Group. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1\u2013150.","journal-title":"Kidney Int Suppl"},{"issue":"99","key":"1994_CR2","first-page":"S1","volume":"2021","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO. clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;2021(99):S1-87.","journal-title":"Kidney Int"},{"key":"1994_CR3","unstructured":"Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021. https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html. Accessed 17 Aug 2021."},{"key":"1994_CR4","doi-asserted-by":"crossref","first-page":"e110535","DOI":"10.1371\/journal.pone.0110535","volume":"9","author":"LA Szczech","year":"2014","unstructured":"Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type\u00a02 diabetes and chronic kidney disease). PLoS\u00a0One. 2014;9:e110535.","journal-title":"PLoS\u00a0One"},{"key":"1994_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","volume":"58","author":"S Blecker","year":"2011","unstructured":"Blecker S, Matsushita K, Kottgen A, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58:47\u201355.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75:84\u2013104.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"1994_CR8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"1994_CR9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253\u20139.","journal-title":"Lancet"},{"key":"1994_CR10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","volume":"139","author":"TH Jafar","year":"2003","unstructured":"Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244\u201352.","journal-title":"Ann Intern Med"},{"key":"1994_CR11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939\u201345.","journal-title":"N Engl J Med"},{"key":"1994_CR12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","volume":"354","author":"P Ruggenenti","year":"1999","unstructured":"Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359\u201364.","journal-title":"Lancet"},{"key":"1994_CR13","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892\u2013903.","journal-title":"N Engl J Med"},{"key":"1994_CR14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"1994_CR15","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type\u00a02 diabetes. N Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"1994_CR16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1994_CR17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type\u00a02 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"1994_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1994_CR19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type\u00a02 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1994_CR20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1994_CR21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink HJ, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"1994_CR22","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"1994_CR23","doi-asserted-by":"crossref","first-page":"697010","DOI":"10.1155\/2015\/697010","volume":"2015","author":"S Toth-Manikowski","year":"2015","unstructured":"Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010.","journal-title":"J Diabetes Res"},{"key":"1994_CR24","doi-asserted-by":"crossref","first-page":"ix26","DOI":"10.1093\/ndt\/gfm446","volume":"22","author":"W Metcalfe","year":"2007","unstructured":"Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant. 2007;22:ix26\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1994_CR25","first-page":"419","volume":"120","author":"RJ Glassock","year":"2009","unstructured":"Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc. 2009;120:419\u201328.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"1994_CR26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/jcm7120493","volume":"7","author":"WC Lee","year":"2018","unstructured":"Lee WC, Lee YT, Li LC, et al. The number of comorbidities predicts renal outcomes in patients with stage 3\u20135 chronic kidney disease. J Clin Med. 2018;7:493.","journal-title":"J Clin Med"},{"key":"1994_CR27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157\u201372.","journal-title":"Circulation"},{"key":"1994_CR28","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies. A scientific statement from the American Heart Association. Circulation. 2019;139:e840\u201378.","journal-title":"Circulation"},{"key":"1994_CR29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/kisup.2013.79","volume":"3","author":"R Kazancioglu","year":"2013","unstructured":"Kazancioglu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl. 2013;3:368\u201371.","journal-title":"Kidney Int Suppl"},{"key":"1994_CR30","doi-asserted-by":"crossref","first-page":"e16420","DOI":"10.1097\/MD.0000000000016420","volume":"98","author":"HS Choi","year":"2019","unstructured":"Choi HS, Han KD, Jung JH, et al. The risk of end-stage renal disease in systemic lupus erythematosus: a nationwide population-based study in Korea. Medicine (Baltimore). 2019;98:e16420.","journal-title":"Medicine (Baltimore)"},{"key":"1994_CR31","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402\u201314.","journal-title":"N Engl J Med"},{"key":"1994_CR32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2020.08.003","volume":"77","author":"KR Tuttle","year":"2021","unstructured":"Tuttle KR, Brosius FC 3rd, Cavender MA, et al. SGLT2 inhibition for CKD and cardiovascular disease in type\u00a02 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021;77:94\u2013109.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR33","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","volume":"305","author":"IH de Boer","year":"2011","unstructured":"de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532\u20139.","journal-title":"JAMA"},{"key":"1994_CR34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. JAMA. 2016;316:602\u201310.","journal-title":"JAMA"},{"key":"1994_CR35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","volume":"16","author":"V Vallon","year":"2020","unstructured":"Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat Rev Nephrol. 2020;16:317\u201336.","journal-title":"Nat Rev Nephrol"},{"key":"1994_CR36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","volume":"31","author":"HM Siragy","year":"2010","unstructured":"Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31:541\u201350.","journal-title":"Am J Nephrol"},{"key":"1994_CR37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/hr.2011.24","volume":"34","author":"R Yang","year":"2011","unstructured":"Yang R, Smolders I, Dupont AG. Blood pressure and renal hemodynamic effects of angiotensin fragments. Hypertens Res. 2011;34:674\u201383.","journal-title":"Hypertens Res"},{"key":"1994_CR38","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1994_CR39","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cphy.c100049","volume":"1","author":"V Vallon","year":"2011","unstructured":"Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol. 2011;1:1175\u2013232.","journal-title":"Compr Physiol"},{"key":"1994_CR40","unstructured":"Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011\u20132014. NCHS Data Brief. 2015;1\u20138."},{"key":"1994_CR41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74:120\u201331.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.HYP.0000145180.38707.84","volume":"44","author":"AK Bidani","year":"2004","unstructured":"Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595\u2013601.","journal-title":"Hypertension"},{"key":"1994_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNH.0b013e32835b36c1","volume":"22","author":"AK Bidani","year":"2013","unstructured":"Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013;22:1\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1994_CR44","first-page":"S79","volume":"73","author":"US Renal Data System","year":"2018","unstructured":"US Renal Data System. 2018 Annual Data Report. Volume 1: CKD in the United States. Chapter 4: cardiovascular disease in patients with CKD. Am J Kidney Dis. 2018;73:S79\u201398.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305.","journal-title":"N Engl J Med"},{"key":"1994_CR46","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1053\/ajkd.2000.19928","volume":"36","author":"A Levin","year":"2000","unstructured":"Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis. 2000;36:S24-30.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR47","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/ATVBAHA.119.312705","volume":"39","author":"JM Valdivielso","year":"2019","unstructured":"Valdivielso JM, Rodriguez-Puyol D, Pascual J, et al. Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol. 2019;39:1938\u201366.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1994_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.ki.5002586","volume":"73","author":"Y Wang","year":"2008","unstructured":"Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19\u201333.","journal-title":"Kidney Int"},{"key":"1994_CR49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","volume":"144","author":"CY Hsu","year":"2006","unstructured":"Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21\u20138.","journal-title":"Ann Intern Med"},{"key":"1994_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ekir.2017.01.010","volume":"2","author":"AR Chang","year":"2017","unstructured":"Chang AR, Grams ME, Navaneethan SD. Bariatric surgery and kidney-related outcomes. Kidney Int Rep. 2017;2:261\u201370.","journal-title":"Kidney Int Rep"},{"key":"1994_CR51","doi-asserted-by":"crossref","first-page":"854","DOI":"10.4158\/EP-2018-0568","volume":"25","author":"CW Mende","year":"2019","unstructured":"Mende CW, Einhorn D. Fatty kidney disease: a new renal and endocrine clinical entity? Describing the role of the kidney in obesity, metabolic syndrome, and type\u00a02 diabetes. Endocr Pract. 2019;25:854\u20138.","journal-title":"Endocr Pract"},{"key":"1994_CR52","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S73\u201384.","journal-title":"Diabetes Care"},{"key":"1994_CR53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","volume":"83","author":"V Perkovic","year":"2013","unstructured":"Perkovic V, Heerspink HL, Chalmers J, et al. Intensive glucose control improves kidney outcomes in patients with type\u00a02 diabetes. Kidney Int. 2013;83:517\u201323.","journal-title":"Kidney Int"},{"key":"1994_CR54","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","volume":"39","author":"MG Wong","year":"2016","unstructured":"Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016;39:694\u2013700.","journal-title":"Diabetes Care"},{"key":"1994_CR55","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1994_CR56","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type\u00a02 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med"},{"key":"1994_CR57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1053\/j.ajkd.2018.07.016","volume":"73","author":"GN Nadkarni","year":"2019","unstructured":"Nadkarni GN, Chauhan K, Rao V, et al. Effect of intensive blood pressure lowering on kidney tubule injury: findings from the ACCORD trial study participants. Am J Kidney Dis. 2019;73:31\u20138.","journal-title":"Am J Kidney Dis"},{"key":"1994_CR58","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:e127-248.","journal-title":"J Am Coll Cardiol"},{"key":"1994_CR59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00041552-200403000-00003","volume":"13","author":"CN Gashti","year":"2004","unstructured":"Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens. 2004;13:155\u201361.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1994_CR60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","volume":"42","author":"PI Georgianos","year":"2019","unstructured":"Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42:693\u2013700.","journal-title":"Diabetes Care"},{"key":"1994_CR61","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/HJH.0000000000001674","volume":"36","author":"RJH Martens","year":"2018","unstructured":"Martens RJH, Houben A, Kooman JP, et al. Microvascular endothelial dysfunction is associated with albuminuria: the Maastricht Study. J Hypertens. 2018;36:1178\u201387.","journal-title":"J Hypertens"},{"key":"1994_CR62","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc13-1870","volume":"37","author":"GL Bakris","year":"2014","unstructured":"Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37:867\u201375.","journal-title":"Diabetes Care"},{"key":"1994_CR63","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","volume":"79","author":"M van der Velde","year":"2011","unstructured":"van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341\u201352.","journal-title":"Kidney Int"},{"key":"1994_CR64","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","volume":"26","author":"HJ Heerspink","year":"2015","unstructured":"Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D, Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol. 2015;26:2055\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"1994_CR65","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","volume":"110","author":"D de Zeeuw","year":"2004","unstructured":"de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type\u00a02 diabetic patients with nephropathy. Circulation. 2004;110:921\u20137.","journal-title":"Circulation"},{"key":"1994_CR66","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"1994_CR67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ndt\/gfab136.002","volume":"36","author":"N Jong","year":"2021","unstructured":"Jong N, Chertow G, Hou FF, et al. Dapagliflozin decreases albuminuria in patients with chronic kidney disease with and without type\u00a02 diabetes: insights from the DAPA-CKD trial. Nephrol Dial Transplant. 2021;36:48.","journal-title":"Nephrol Dial Transplant"},{"key":"1994_CR68","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type\u00a02 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1994_CR69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3803\/EnM.2019.34.1.80","volume":"34","author":"JH Bae","year":"2019","unstructured":"Bae JH, Kim S, Park EG, Kim SG, Hahn S, Kim NH. Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type\u00a02 diabetes: a systematic review and meta-analysis. Endocrinol Metab. 2019;34:80\u201392.","journal-title":"Endocrinol Metab"},{"key":"1994_CR70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","volume":"40","author":"O Mosenzon","year":"2017","unstructured":"Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40:69\u201376.","journal-title":"Diabetes Care"},{"key":"1994_CR71","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report, 2020. https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf. Accessed 31 May 2020."},{"key":"1994_CR72","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018. NCHS Data Brief. 2020;1\u20138."},{"key":"1994_CR73","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1681\/ASN.2005060638","volume":"17","author":"E Ejerblad","year":"2006","unstructured":"Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006;17:1695\u2013702.","journal-title":"J Am Soc Nephrol"},{"key":"1994_CR74","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/ndt\/gfp640","volume":"25","author":"F Afshinnia","year":"2010","unstructured":"Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant. 2010;25:1173\u201383.","journal-title":"Nephrol Dial Transplant"},{"key":"1994_CR75","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2215\/CJN.02250409","volume":"4","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:1565\u201374.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1994_CR76","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"1994_CR77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","volume":"153","author":"SC Palmer","year":"2010","unstructured":"Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23\u201333.","journal-title":"Ann Intern Med"},{"key":"1994_CR78","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40620-019-00656-5","volume":"32","author":"BR Di Iorio","year":"2019","unstructured":"Di Iorio BR, Bellasi A, Raphael KL, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019;32:989\u20131001.","journal-title":"J Nephrol"},{"key":"1994_CR79","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","volume":"44","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Wiviott SD, Heerspink HJL, et al. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021;44:1805\u201315.","journal-title":"Diabetes Care"},{"key":"1994_CR80","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stefansson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1994_CR81","unstructured":"US Food and Drug Administration. Invokana (canagliflozin) tablets, for oral use [prescribing information]. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204042s034lbl.pdf. Accessed 14 June 2021."},{"key":"1994_CR82","unstructured":"US Food and Drug Administration. Farxiga\u00ae (dapagliflozin) tablets, for oral use [prescribing information]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202293s024lbl.pdf. Accessed 14 June 2021."},{"key":"1994_CR83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type\u00a02 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97:202\u201312.","journal-title":"Kidney Int"},{"key":"1994_CR84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter\u00a02 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587\u201397.","journal-title":"Circulation"},{"key":"1994_CR85","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Cherney DZI. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol. 2021;16:1278\u201380.","DOI":"10.2215\/CJN.02480221"},{"key":"1994_CR86","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate \u201cdip\u201d upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99:750\u201362.","journal-title":"Kidney Int"},{"key":"1994_CR87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.aace.2020.11.009","volume":"7","author":"S Mistry","year":"2021","unstructured":"Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep. 2021;7:17\u20139.","journal-title":"AACE Clin Case Rep"},{"key":"1994_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.09.005","author":"HJ Heerspink","year":"2021","unstructured":"Heerspink HJ, Cherney D, Postmus D, et al. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence ofabrupt declines in kidney function. Kidney Int. 2021. https:\/\/doi.org\/10.1016\/j.kint.2021.09.005.","journal-title":"Kidney Int"},{"key":"1994_CR89","unstructured":"US Food and Drug Administration. Jardiance\u00ae (empagliflozin) tablets, for oral use [prescribing information]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204629s000lbl.pdf. Accessed 17 Aug 2021."},{"key":"1994_CR90","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2215\/CJN.11220720","volume":"16","author":"M Zhao","year":"2020","unstructured":"Zhao M, Sun S, Huang Z, Wang T, Tang H. Network meta-analysis of novel glucose-lowering drugs on risk of acute kidney injury. Clin J Am Soc Nephrol. 2020;16:70\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1994_CR91","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","volume":"75","author":"CS Wilcox","year":"2020","unstructured":"Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter\u00a02) inhibitors. Hypertension. 2020;75:894\u2013901.","journal-title":"Hypertension"},{"key":"1994_CR92","doi-asserted-by":"crossref","first-page":"e10242","DOI":"10.1002\/jbm4.10242","volume":"3","author":"G Cianciolo","year":"2019","unstructured":"Cianciolo G, De Pascalis A, Capelli I, et al. Mineral and electrolyte disorders with SGLT2i therapy. JBMR Plus. 2019;3:e10242.","journal-title":"JBMR Plus"},{"key":"1994_CR93","doi-asserted-by":"publisher","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy [supplemental appendix]. N Engl J Med. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744\/suppl_file\/nejmoa_appendix.pdf. Accessed 5 Oct 2021.","DOI":"10.1056\/NEJMoa1811744\/suppl_file\/nejmoa_appendix.pdf"},{"key":"1994_CR94","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","volume":"143","author":"N Ye","year":"2021","unstructured":"Ye N, Jardine MJ, Oshima M, et al. Blood pressure effects of canagliflozin and clinical outcomes in type\u00a02 diabetes and chronic kidney disease: insights from the CREDENCE Trial. Circulation. 2021;143:1735\u201349.","journal-title":"Circulation"},{"key":"1994_CR95","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","volume":"5","author":"LY Herat","year":"2020","unstructured":"Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection. JACC Basic Transl Sci. 2020;5:169\u201379.","journal-title":"JACC Basic Transl Sci"},{"key":"1994_CR96","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1994_CR97","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","volume":"8","author":"AP McGovern","year":"2020","unstructured":"McGovern AP, Hogg M, Shields BM, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8:e001238.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1994_CR98","unstructured":"US Food and Drug Administration. Kerendia (finerenone) tablets, for oral use [prescribing information]. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215341s000lbl.pdf. Accessed 17 Aug 2021."},{"key":"1994_CR99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type\u00a02 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131\u20138.","journal-title":"Lancet"},{"key":"1994_CR100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type\u00a02 diabetes. N Engl J Med. 2017;377:839\u201348.","journal-title":"N Engl J Med"},{"key":"1994_CR101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type\u00a02 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:859\u201369.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01994-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01994-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T03:47:59Z","timestamp":1643341679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01994-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01994-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}